The FDA has approved a fixed-duration, all-oral regimen of acalabrutinib plus venetoclax for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The decision, ...

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

Genetic predisposition and lifestyle factors both play crucial roles in diabetes management and onset. Cancer treatment can complicate diabetes management, requiring careful coordination between ...

Lori A. Leslie, MD, and Hoshiyuki Iida, APN, provide an overview of chronic lymphocytic leukemia and the risk stratification process. Lori A. Leslie, MD: Hello, and welcome to CURE Expert Connections® ...

CLL is the most prevalent form of chronic leukemia in adults. By providing emotional support to a friend or family member with CLL, you increase their chances for an improved quality of life. To get ...

Prevalence rates of chronic lymphocytic leukemia have steadily increased over the last 30 years, and are projected to continue to rise. Survival rates have steadily increased among all age groups ...

Matching-adjusted indirect comparison methodology was utilized to compare ibrutinib arms across the ALPINE and ELEVATE-RR trials. In each study, ibrutinib was used as the comparator for a ...

High correlation between TMB, expressed TMB, and neoantigen load using tumor: Normal whole exome DNA and matched whole transcriptome RNA sequencing. Cross-site concordance evaluation for the ...

Most patients with chronic lymphocytic leukemia (CLL) have an indolent clinical course, but the disease remains incurable with standard therapy and the prognosis is dismal for those patients with ...